For the Inventor, By the Inventor

Enter assignee name

La Jolla, CA, United States of America

Avidity Biosciences, Inc.

USPTO Granted Patents = 47

EPO Patents = 5

Trademarks = 31

Forward Citations = 386

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Rob Burke (38 out of 41 patents)

Venkata Ramana Doppalapudi (35 out of 42 patents)

Michael Caramian Cochran (32 out of 34 patents)

4. Beatrice Diana Darimont (32 out of 32 patents)

5. Andrew John Geall (24 out of 99 patents)

6. Barbora Malecova (24 out of 24 patents)

7. David Sai-Ho Chu (21 out of 21 patents)

8. Gulin Erdogan Marelius (13 out of 18 patents)

9. Yunyu Shi (13 out of 13 patents)

10. Michael David Hood (13 out of 13 patents)

11. Rachel Elizabeth Johns (9 out of 9 patents)

12. Hanhua Huang (8 out of 8 patents)

13. David Sala Cano (8 out of 8 patents)

14. Palani Balu (6 out of 14 patents)

15. Arthur A Levin (5 out of 5 patents)

47 patents: Sort by Forward Citations

1. 12427202 - Compositions and methods of treating muscle dystrophy (2025-09-30),

2. 12409230 - Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy (2025-09-09),

3. 12365704 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),

4. 12364769 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),

5. 12359202 - Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping (2025-07-15),

6. 12351637 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-08),

7. 12263224 - Compositions and methods of treating muscle atrophy and myotonic dystrophy (2025-04-01),

8. 12234290 - Nucleic acid-polypeptide compositions and uses thereof (2025-02-25),

9. 12157774 - Compositions and methods of treating facioscapulohumeral muscular dystrophy (2024-12-03),

10. 12104156 - Compositions and methods of treating facioscapulohumeral muscular dystrophy (2024-10-01),

11. 12071621 - Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping (2024-08-27),

12. 12071485 - Compositions and methods of treating facioscapulohumeral muscular dystrophy (2024-08-27),

13. 12064483 - Nucleic acid-polypeptide compositions and methods of inducing exon skipping (2024-08-20),

14. 12049629 - Compositions and methods of treating Facioscapulohumeral muscular dystrophy (2024-07-30),

15. 12006499 - Una amidites and uses thereof (2024-06-11),

Avidity Biosciences is a biotechnology company focused on the development of targeted therapies for the treatment of rare muscle disorders. They are pioneering a proprietary technology platform called AOCs (Arcus™ Occurrence Catalytic System) that enables the targeted delivery of nucleic acids to muscle tissue. Avidity Biosciences is dedicated to advancing its pipeline of potential therapies to address the unmet needs of patients with rare muscle diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

47 Patents

#16 in La Jolla, CA

#1,709 in California

#7,164 in US

#14,382 in the World

La Jolla, CA, United States of America

Avidity Biosciences, Inc.

Forward Citations = 386

25 inventors:

Rob Burke (38 out of 41 patents)

Venkata Ramana Doppalapudi (35 out of 42 patents)

Michael Caramian Cochran (32 out of 34 patents)

4. Beatrice Diana Darimont (32 out of 32 patents)

5. Andrew John Geall (24 out of 99 patents)

Please report any incorrect information to support@idiyas.com

Loading…